RxDoctor Payments Data

Edmond Bendaly, MD

Hematology & Oncology · Marion, INNPI 1285835652

Payments from drug & device makers

$46,982in general payments, 2019–2025

Across 558 payments — averaging $84.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Incyte Corporation$4K
  • Taiho Oncology, Inc.$3K
  • Gilead$2K
  • GSK$2K
  • plus $16K from 53 others

What the payments were for

  • Consulting fees$30,79971%
  • Speaking & faculty fees$2,7606%
  • Food & beverage$9,07821%
  • Education$4931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)27$11,438
E.r. Squibb & Sons, L.L.C.99$8,834
Incyte Corporation6$3,908
Taiho Oncology, Inc.1$2,640
Gilead(2 entities)22$2,106
GSK6$2,012
Lilly USA, LLC11$1,943
Beone Medicines USA, Inc.1$1,833
Seagen Inc.8$1,392
Rigel Pharmaceuticals, Inc.1$1,200
Exelixis Inc.6$1,078
Pfizer62$912
Daiichi Sankyo Inc.12$859
Novartis57$840
Johnson & Johnson(2 entities)27$710
Beigene USA, Inc.1$675
Bristol Myers Squibb29$646
Merck29$490
Genentech USA, Inc.19$343
Sanofi12$329
AbbVie18$310
Astellas Pharma US Inc12$287
Array Biopharma Inc18$273
Sirtex Medical Inc1$218
Novocure GmbH1$200
Pharmacyclics LLC, An Abbvie Company3$130
Servier Pharmaceuticals LLC5$105
Pharmaessentia USA Corporation5$102
Comsort, Inc1$100
Boehringer Ingelheim4$95
Adaptive Biotechnologies Corporation5$91
Jazz Pharmaceuticals Inc.5$88
Amgen5$80
Eisai Inc.4$60
AVEO Pharmaceuticals, Inc.3$55
Ipsen Biopharmaceuticals, Inc2$48
Tempus AI, Inc2$46
Sumitomo Pharma America, Inc.2$42
Acrotech Biopharma Inc.2$42
Takeda Pharmaceuticals U.S.A., Inc.2$42
Regeneron Healthcare Solutions, Inc.2$38
Foundation Medicine, Inc.2$36
Mirati Therapeutics, Inc.1$28
Teva Pharmaceuticals USA, Inc.2$24
Agios Pharmaceuticals, Inc.1$23
Iovance Biotherapeutics, Inc.1$23
Alnylam Pharmaceuticals Inc.1$22
CTI Biopharma Corp.1$18
Legend Biotech USA Inc.1$18
ADC Therapeutics America, Inc.1$18
Puma Biotechnology, Inc.1$17
Genmab U.S., Inc.1$16
Portola Pharmaceuticals, LLC1$16
Stemline Therapeutics Inc.1$16
Springworks Therapeutics, Inc.1$16
Blueprint Medicines Corporation1$15
Helsinn Therapeutics (U.S.), Inc.1$13
Roche Diagnostics Corporation1$12
Janssen Scientific Affairs, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,982 in reported general payments places this provider in the 65th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$136,041
Medicare patients
313
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl24$358,580
JakafiRuxolitinib Phosphate16$316,175
Lenalidomide23$246,346
VerzenioAbemaciclib16$240,756
BrukinsaZanubrutinib15$225,753
RevlimidLenalidomide13$193,775
CalquenceAcalabrutinib Maleate12$183,150
Abiraterone Acetate51$78,471
EliquisApixaban94$65,219
XareltoRivaroxaban45$29,786
Enoxaparin Sodium13$4,407
Exemestane14$3,624
Posaconazole17$3,239
Ondansetron OdtOndansetron155$2,318
Prochlorperazine Maleate109$2,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$840$358,58024 claims
Incyte CorporationJakafi$3,908$316,17516 claims
Lilly USA, LLCVerzenio$1,943$240,75616 claims
Beigene USA, Inc.Brukinsa$675$225,75315 claims
Bristol Myers SquibbRevlimid$646$193,77513 claims
AstraZenecaCalquence$11,438$183,15012 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$11$78,47151 claims
PfizerEliquis$912$65,21994 claims
Johnson & JohnsonXarelto$710$29,78645 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$24$88866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →